G. J. Ossenkoppele

414 total citations
17 papers, 279 citations indexed

About

G. J. Ossenkoppele is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, G. J. Ossenkoppele has authored 17 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 14 papers in Genetics and 8 papers in Rheumatology. Recurrent topics in G. J. Ossenkoppele's work include Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Eosinophilic Disorders and Syndromes (8 papers). G. J. Ossenkoppele is often cited by papers focused on Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Eosinophilic Disorders and Syndromes (8 papers). G. J. Ossenkoppele collaborates with scholars based in Netherlands, United States and Germany. G. J. Ossenkoppele's co-authors include Andreas Hochhaus, Neil J. Gallagher, Michele Baccarani, Francis J. Giles, Jörge E. Cortes, Hagop M. Kantarjian, Edo Vellenga, Hendrik J.M. de Jonge, Jan Jacob Schuringa and Eveline S.J.M. de Bont and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and Haematologica.

In The Last Decade

G. J. Ossenkoppele

17 papers receiving 270 citations

Peers

G. J. Ossenkoppele

HEMAT

GENET

RHEUM

PHEOH

ONCOL

Charlene So United States

Daniella Kerbauy United States

Alicia Enrico Argentina

Bronte A. Jamison Australia

Alexandra L. Yeoman Australia

Shanti Amé France

Nelma Cristina D. Clementino Brazil

Jeffrey Skinner United States

Simone Claudiani United Kingdom

Fabian Lang Germany

Charlene So United States

G. J. Ossenkoppele

257 ×1.0

HEMAT

224 ×1.1

GENET

158 ×1.2

RHEUM

26 ×0.6

PHEOH

22 ×0.8

ONCOL

Citations per year, relative to G. J. Ossenkoppele G. J. Ossenkoppele (= 1×) peers Charlene So

Countries citing papers authored by G. J. Ossenkoppele

Since Specialization

Citations

This map shows the geographic impact of G. J. Ossenkoppele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. J. Ossenkoppele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. J. Ossenkoppele more than expected).

Fields of papers citing papers by G. J. Ossenkoppele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. J. Ossenkoppele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. J. Ossenkoppele. The network helps show where G. J. Ossenkoppele may publish in the future.

Co-authorship network of co-authors of G. J. Ossenkoppele

This figure shows the co-authorship network connecting the top 25 collaborators of G. J. Ossenkoppele. A scholar is included among the top collaborators of G. J. Ossenkoppele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. J. Ossenkoppele. G. J. Ossenkoppele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Hughes, Timothy P., Andreas Hochhaus, Hagop M. Kantarjian, et al.. (2014). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 99(7). 1204–1211. 37 indexed citations

Coutre, Philipp D. le, Francis J. Giles, Andreas Hochhaus, et al.. (2011). Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 26(6). 1189–1194. 63 indexed citations

Jonge, Hendrik J.M. de, Peter J.M. Valk, Eveline S.J.M. de Bont, et al.. (2011). Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 96(9). 1310–1317. 59 indexed citations

Niederwieser, D, Enrica Morra, Mauricette Michallet, et al.. (2011). Delaying the initiation of dasatinib after imatinib failure has a negative impact on outcome for patients with chronic-phase chronic myeloid leukemia (CP-CML): results from a European observational study (FORTE; CA180-211). 34. 264–264. 1 indexed citations

Steegmann, J. L., Mauricette Michallet, Enrica Morra, et al.. (2010). A european observational study of dasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: forte study (ca180-211). 95. 339–339. 1 indexed citations

Coutre, Philipp D. le, F. Giles, Andreas Hochhaus, et al.. (2009). Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. Journal of Clinical Oncology. 27(15_suppl). 7057–7057. 24 indexed citations

Cervantes, Francisco, Mammen Chandy, Thorsten Fischer, et al.. (2008). Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Journal of Clinical Oncology. 26(15_suppl). 7001–7001. 15 indexed citations

Steegmann, Juan Luis, et al.. (2008). Imatinib use in chronic phase CML in clinical practice: the UNIC study. Journal of Clinical Oncology. 26(15_suppl). 7077–7077. 6 indexed citations

Abruzzese, Elisabetta, G. Alimena, Philipp le Coutre, et al.. (2008). Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study. Journal of Clinical Oncology. 26(15_suppl). 7055–7055. 9 indexed citations

10.

Kantarjian, Hagop M., Francis J. Giles, Andreas Hochhaus, et al.. (2008). Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. Journal of Clinical Oncology. 26(15_suppl). 7010–7010. 18 indexed citations

11.

Rosti, G., Philipp le Coutre, Kapil N. Bhalla, et al.. (2007). A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Journal of Clinical Oncology. 25(18_suppl). 7007–7007. 13 indexed citations

12.

Giles, Francis J., Philipp le Coutre, Kapil N. Bhalla, et al.. (2007). A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. Journal of Clinical Oncology. 25(18_suppl). 7038–7038. 12 indexed citations

13.

Jabbour, Elias, Philipp le Coutre, Michele Baccarani, et al.. (2007). Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP). Journal of Clinical Oncology. 25(18_suppl). 7039–7039. 4 indexed citations

14.

Deenik, Wendy, Bronno van der Holt, G. Verhoef, et al.. (2006). High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. Annals of Hematology. 86(2). 117–125. 5 indexed citations

15.

Ossenkoppele, G. J., et al.. (2003). [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].. PubMed. 147(30). 1460–5. 2 indexed citations

16.

Löwenberg, Bob, et al.. (2002). [STI571: a new dimension in the treatment of chronic myeloid leukemia].. PubMed. 146(3). 128–32. 1 indexed citations

17.

Ossenkoppele, G. J., et al.. (1998). Costs of intensive treatment and follow-up of patients with multiple myeloma. Anti-Cancer Drugs. 9(10). 889–898. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact